BioNTech SE: all 124 studies

Page 1 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational DrugsNot yet recruitingNCT07893054Phase 1
• A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-TnNot yet recruitingNCT07886684Phase 1/2
• A Study of COVID-19 Vaccine(s) in Children and AdultsRecruitingNCT07798648Phase 3
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingNCT07730450Phase 4
• A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVRecruitingNCT07698600Phase 1
• Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid TumorsRecruitingNCT07455734Phase 1/2
• A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVRecruitingNCT07392372Phase 1
• A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaRecruitingNCT07379580Phase 2
• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerRecruitingNCT07365995Phase 3
• A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaRecruitingNCT07297212Phase 2
• A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic CancerRecruitingNCT07255404Phase 2
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9RecruitingNCT07186842Phase 1/2
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingNCT07173751Phase 3
• A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid TumorsRecruitingNCT07147348Phase 1/2
• PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerRecruitingNCT07133750Phase 2
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07111520Phase 1/2
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerRecruitingNCT07079631Phase 1/2
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Phase 1/2
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingNCT06892548Phase 1/2
• Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentRecruitingNCT06841055Phase 2
• A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerRecruitingNCT06827236Phase 1/2
• Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsRecruitingNCT06750185Phase 1/2
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingNCT06712355Phase 3
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Phase 2/3
• A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruitingNCT06584071Phase 1/2
• A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingNCT06340568Phase 3
• A Study of PM1015 in Patients With Advanced Solid TumorsRecruitingNCT05950815Phase 1
• PM8002 in the Treatment of Patients With Advanced Solid TumorsRecruitingNCT05918445Phase 1/2
• A Study of PM1022 in Patients With Advanced TumorsRecruitingNCT05867771Phase 1/2
• Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid TumorsRecruitingNCT05862831Phase 1/2
• Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid TumorsRecruitingNCT05839106Phase 1/2
• A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid TumoursNot yet recruitingNCT05537051Phase 1
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingNCT05142189Phase 1
• A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeopleCompletedNCT06683352Phase 1/2Results posted
• A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial VaginosisCompletedNCT06469164Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.CompletedNCT06178991Phase 3Results posted
• Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic AdenocarcinomaTerminatedNCT06069778Phase 1/2Results posted
• A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaCompletedNCT06069544Phase 1/2Results posted
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsCompletedNCT05997290Phase 2/3Results posted
• A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesCompletedNCT05988203Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and InfluenzaCompletedNCT05596734Phase 2Results posted
• Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaCompletedNCT05581641Phase 1Results posted
• Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy PeopleCompletedNCT05541861Phase 1Results posted
• A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy IndividualsCompletedNCT05472038Phase 2/3Results posted
• Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of AgeCompletedNCT05310084Phase 3Results posted
• Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy ParticipantsCompletedNCT05004181Phase 2Results posted
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.CompletedNCT04955626Phase 3Results posted
• A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial SubjectsCompletedNCT04949490Phase 2Results posted
• Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 YearsCompletedNCT04895982Phase 2Results posted
• COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbiditiesTerminatedNCT04860258Phase 3Results posted
• A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy AdultsCompletedNCT04816669Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedNCT04816643Phase 3Results posted
• To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and OlderCompletedNCT04754594Phase 2/3Results posted
• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy ParticipantsCompletedNCT04713553Phase 3Results posted
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsTerminatedNCT04683939Phase 1/2Results posted
• A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19CompletedNCT04674189Phase 3Results posted
• A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and OlderCompletedNCT04652102Phase 2/3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese AdultsCompletedNCT04588480Phase 4Results posted
• A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy AdultsCompletedNCT04537949Phase 1/2Results posted
• A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentCompletedNCT04526899Phase 2Results posted
• Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy SubjectsCompletedNCT04523571Phase 1Results posted
• A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04515147Phase 2Results posted
• BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid TumorsTerminatedNCT04455620Phase 1/2Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04449276Phase 1Results posted
• PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)TerminatedNCT04382898Phase 1/2Results posted
• A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised AdultsCompletedNCT04380701Phase 1/2Results posted
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsCompletedNCT04368728Phase 2/3Results posted
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411TerminatedNCT04101357Phase 1/2Results posted
• A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy AdultsCompletedNCT03713086Phase 1Results posted
• Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"CompletedNCT02244580Not applicableResults posted
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCompletedNCT07300839Phase 3
• A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19CompletedNCT07222384Phase 3
• Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)WithdrawnNCT07073183Phase 1
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsCompletedNCT07069309Phase 3
• A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From SpermWithdrawnNCT06940804Phase 2
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleCompletedNCT06821061Phase 1/2
• PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerActive, not recruitingNCT06616532Phase 3
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyActive, not recruitingNCT06449222Phase 2
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyActive, not recruitingNCT06449209Phase 2
• PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Phase 3
• Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid TumorsActive, not recruitingNCT06150183Phase 1
• Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or AstrocytomaCompletedNCT05938387Phase 1
• A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCActive, not recruitingNCT05918133Phase 1/2
• A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMCompletedNCT05918107Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With NENActive, not recruitingNCT05879055Phase 2
• PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Phase 2
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Phase 2
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT05756972Phase 2
• A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and ChildrenWithdrawnNCT05630352Phase 1
• A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced TumoursStatus unknownNCT05607563Phase 1
• Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated VolunteersActive, not recruitingNCT05547464Phase 1/2
• A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenCompletedNCT05543616Phase 3
• Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy VolunteersCompletedNCT05537038Phase 1
• A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes LesionsActive, not recruitingNCT05432583Phase 1
• Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid TumorsTerminatedNCT05262530Phase 1/2
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy AdultsCompletedNCT05252338Phase 1
• A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19WithdrawnNCT04838847Phase 3
• Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant ChemotherapyCompletedNCT04813627
• Dose Escalation Trial of BNT152+153 in Patients With CancerCompletedNCT04710043Phase 1

← BioNTech SE overview and focus areas